Arca
Skip to content
Tools
Tools

Myasthenia gravis

Drug research and approvals for myasthenia gravis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 89 studies of myasthenia gravis are recruiting on ClinicalTrials.gov, Health Canada has authorized 59 drug trials for it since 2013, FDA has 13 approved and 27 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 89
  • Trials authorized in Canada: 59
  • FDA orphan approvals: 13
  • EU medicines: 5

Recruiting now

Newest posted first, of 89 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 7

Phase 3 12 of 18

Phase 2 10

Phase 1 or earlier 6

How its trials ended

235 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 45 whose ending is known, 49% met their primary endpoint, 13% missed it and 38% stopped early.

  • Ongoing10344%
  • Completed, result not reported6226%
  • Status unknown2511%
  • Met its primary endpoint229%
  • Stopped: other or unclear83%
  • Missed its primary endpoint63%
  • Stopped: sponsor or business decision52%
  • Stopped: enrollment or feasibility31%
  • Stopped: lack of efficacy1<1%

Trials authorized in Canada

The 10 newest of 59; search them all in Canada trials
Oct 30, 2026A phase 3, randomized, double-masked, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics,…Klygefa (gefurulimab (ALXN1720))AstraZeneca PharmaceuticalsPending
Jul 29, 2026A phase 3 global, multicenter, randomized, double-blind, placebo-controlled study to demonstrate the efficacy, safety, and tolerability of claseprubart…Claseprubart (DNTH103)Dianthus TherapeuticsPending
May 26, 2026A phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravisRystiggo (UCB7665)UCBOngoing
Apr 28, 2026A double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of aritinercept, a dual baff/april inhibitor, in patients with…Aritinercept (AUR200)Aurinia PharmaceuticalsOngoing
Apr 8, 2026A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular…Rozanolixizumab (UCB7665)UCBOngoing
Dec 2, 2025A phase 1b/2, multicenter, randomized, double-blind, placebo-controlled study to investigate a) the safety, tolerability, pharmacokinetics, and…IM-101Immunabs Inc.Pending
Nov 13, 2025A phase 2 open-label multicenter study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of inebilizumab in children from 2 years to…UpliznaAmgenClosed
Aug 1, 2025A randomized, double-blind, placebo-controlled phase 3 trial of descartes-08 in patients with acetylcholine receptor antibody-positive generalized myasthenia…Descartes-08Cartesian TherapeuticsOngoing
Jul 18, 2025A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized…Iptacopan (LNP063)Novartis PharmaceuticalsClosed
May 8, 2025A phase 3, randomized, double-blind, placebo-controlled study with an open-label extension period to evaluate the efficacy and safety of telitacicept in…Telitacicept (RC18, RC18-L)Vor BiopharmaClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 40
Nov 13, 2026KlygefaTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positiveAlexion Pharmaceuticals, Inc.Approved
May 8, 2026Vyvgart HytruloTreatment of adult patients with generalized myasthenia gravis (gMG)argenx BVApproved
May 8, 2026VyvgartTreatment of adult patients with generalized myasthenia gravis (gMG)argenx BVApproved
Dec 11, 2025UpliznaTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific…Horizon Therapeutics Ireland Designated Activity Company (a subsidiary of Amgen Inc.)Approved
Apr 29, 2025ImaavyTreatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine…Janssen Research & Development, LLCApproved
Apr 10, 2025Vyvgart HytruloTreatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positiveargenx BVApproved
Feb 28, 2025SolirisTreatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine…Alexion Pharmaceuticals, Inc.Approved
Oct 17, 2023ZilbrysqTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positiveUCB, Inc.Approved
Jun 26, 2023RystiggoTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific…UCB, Inc.Approved
Jun 20, 2023Vyvgart HytruloTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positiveargenx BVApproved
Apr 27, 2022UltomirisTreatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positiveAlexion Pharmaceuticals, Inc.Approved
Dec 17, 2021VyvgartTreatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positiveargenx BVApproved
Oct 23, 2017SolirisFor the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positiveAlexion Pharmaceuticals, Inc.Approved
May 1, 2026ClaseprubartTreatment of myasthenia gravisDianthus Therapeutics, Inc.Designated
Feb 2, 2026PovetaciceptTreatment of generalized myasthenia gravis (gMG)Vertex Pharmaceuticals IncorporatedDesignated

Medicines authorised in the EU

Newest first
Nov 28, 2025ImaavyNipocalimabJanssen Cilag International NVEMA ↗
Jan 5, 2024RystiggoRozanolixizumab · orphanUCB PharmaEMA ↗
Dec 1, 2023ZilbrysqZilucoplanUCB Pharma S.A.EMA ↗
Aug 10, 2022VyvgartEfgartigimod alfa · orphanArgenxEMA ↗
May 19, 2022Amifampridine SERBAmifampridine · genericSerb SAEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.